DNMT3L

DNMT3L

A gene on chromosome 21q22.3 that encodes a nuclear protein with similarity to DNA methyltransferases, which is not thought to function as a DNA methyltransferase, as it lacks the amino acid residues needed for methyltransferase activity, but does stimulate de novo methylation by DNA cytosine methyltransferase 3 alpha and is required for establishing maternal genomic imprints. It also mediates transcriptional repression by interacting with histone deacetylase 1.
Mentioned in ?
References in periodicals archive ?
15,16) DNMT3L is highly expressed in gametes and is a known factor responsible for the acquisition of imprints during gametogenesis.
DNA methylation analysis of the DNMT3L promoter was carried out using the sodium bisulfite-assisted genomic DNA conversion method described previously by Gokul et al (18) Briefly, 1 mg of genomic DNA was denatured and mixed with low-melting agarose (BMA, Rockland, Maine) and pipetted into cold, heavy mineral oil (Sigma-Aldrich, St Louis, Missouri) to form beads.
The differences in DNA methylation levels at the DNMT3L promoter in OSSN and in healthy conjunctiva were analyzed using the t test for each CpG at all loci examined.
We studied the methylation levels of 11 CpG dinucleotides in the DNMT3L promoter.
24) Given that the DNMT3L promoter has been shown to be hypomethylated in cervical cancers, we evaluated for methylation differences at this locus using a limited number of OSSN tumors.
Results from this pilot study indicate that varying degrees of hypomethylation can occur in the DNMT3L promoter region in OSSN.
Our data are corroborated by previous studies showing hypomethylation at the DNMT3L promoter in cervical cancer.
Isolation and initial characterization of a novel zinc finger gene, DNMT3L, on 21q22.
The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by Dnmt3a.
DNMT3L stimulates the DNA methylation activity of Dnmt3a and Dnmt3b through a direct interaction.
DNA methylation profile at the DNMT3L promoter: a potential biomarker for cervical cancer.
FIT Biotech has also built an impressive intellectual property portfolio and has filed numerous international patents for its technology and the applications based on it, including novel vectors (GTU), medical devices (device and gene therapy), self-replicating vectors for DNA immunization against HIV, AIRE (immunological mechanisms) and DNMT3L (immune diseases, new genes).